Jennison Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $231M | Sell |
1,062,732
-124,242
| -10% | -$27.6M | 0.16% | 64 |
|
|
2025
Q4 | $271M | Buy |
1,186,974
+566,990
| +91% | +$129M | 0.16% | 60 |
|
|
2025
Q3 | $144M | Buy |
619,984
+10,808
| +2% | +$2.2M | 0.08% | 97 |
|
|
2025
Q2 | $113M | Sell |
609,176
-135,764
| -18% | -$25.2M | 0.07% | 124 |
|
|
2025
Q1 | $156M | Sell |
744,940
-129,131
| -15% | -$25.1M | 0.11% | 95 |
|
|
2024
Q4 | $155M | Sell |
874,071
-857,207
| -50% | -$158M | 0.09% | 99 |
|
|
2024
Q3 | $342M | Buy |
1,731,278
+145,542
| +9% | +$27.2M | 0.21% | 60 |
|
|
2024
Q2 | $272M | Sell |
1,585,736
-574,719
| -27% | -$95.2M | 0.17% | 60 |
|
|
2024
Q1 | $393M | Buy |
2,160,455
+233,987
| +12% | +$40.3M | 0.26% | 52 |
|
|
2023
Q4 | $299M | Buy |
1,926,468
+421,533
| +28% | +$61.5M | 0.22% | 56 |
|
|
2023
Q3 | $224M | Buy |
1,504,935
+2,027
| +0.1% | +$298K | 0.19% | 60 |
|
|
2023
Q2 | $202M | Sell |
1,502,908
-36,561
| -2% | -$5.36M | 0.17% | 65 |
|
|
2023
Q1 | $245M | Sell |
1,539,469
-505,661
| -25% | -$77.3M | 0.23% | 62 |
|
|
2022
Q4 | $331M | Buy |
2,045,130
+67,677
| +3% | +$10.4M | 0.34% | 54 |
|
|
2022
Q3 | $265M | Buy |
1,977,453
+555,903
| +39% | +$79.8M | 0.26% | 55 |
|
|
2022
Q2 | $218M | Sell |
1,421,550
-507,311
| -26% | -$77.5M | 0.22% | 62 |
|
|
2022
Q1 | $313M | Buy |
1,928,861
+50,443
| +3% | +$7.33M | 0.23% | 61 |
|
|
2021
Q4 | $254M | Buy |
1,878,418
+11,728
| +0.6% | +$1.39M | 0.16% | 66 |
|
|
2021
Q3 | $201M | Buy |
1,866,690
+795,754
| +74% | +$90.9M | 0.13% | 74 |
|
|
2021
Q2 | $121M | Buy |
1,070,936
+333,065
| +45% | +$37.5M | 0.08% | 111 |
|
|
2021
Q1 | $79.9M | Buy |
737,871
+73,606
| +11% | +$7.87M | 0.06% | 150 |
|
|
2020
Q4 | $71.2M | Buy |
664,265
+118,166
| +22% | +$11.4M | 0.05% | 149 |
|
|
2020
Q3 | $47.8M | Buy |
546,099
+104,234
| +24% | +$9.81M | 0.04% | 189 |
|
|
2020
Q2 | $43.4M | Buy |
441,865
+427,432
| +2,961% | +$37.6M | 0.04% | 188 |
|
|
2020
Q1 | $1.1M | Buy |
+14,433
| New | +$1.23M | ﹤0.01% | 486 |
|
|
2018
Q3 | – | Sell |
-222,278
| Closed | -$20.6M | – | 659 |
|
|
2018
Q2 | $20.6M | Sell |
222,278
-5,970,070
| -96% | -$583M | 0.02% | 397 |
|
|
2018
Q1 | $586M | Sell |
6,192,348
-5,161,397
| -45% | -$567M | 0.58% | 47 |
|
|
2017
Q4 | $1.1B | Buy |
11,353,745
+5,227,056
| +85% | +$493M | 1.08% | 29 |
|
|
2017
Q3 | $544M | Buy |
+6,126,689
| New | +$466M | 0.56% | 46 |
|
|
2017
Q1 | – | Sell |
-407,581
| Closed | -$25.5M | – | 639 |
|
|
2016
Q4 | $25.5M | Sell |
407,581
-1,904,692
| -82% | -$116M | 0.03% | 380 |
|
|
2016
Q3 | $146M | Sell |
2,312,273
-42,199
| -2% | -$2.73M | 0.16% | 110 |
|
|
2016
Q2 | $146M | Sell |
2,354,472
-4,773
| -0.2% | -$291K | 0.16% | 114 |
|
|
2016
Q1 | $135M | Sell |
2,359,245
-310,414
| -12% | -$17.3M | 0.14% | 120 |
|
|
2015
Q4 | $158M | Sell |
2,669,659
-394,017
| -13% | -$22.7M | 0.16% | 106 |
|
|
2015
Q3 | $167M | Buy |
3,063,676
+655,980
| +27% | +$42.7M | 0.17% | 107 |
|
|
2015
Q2 | $162M | Buy |
+2,407,696
| New | +$157M | 0.15% | 122 |
|
|
2015
Q1 | – | Sell |
-2,217,677
| Closed | -$145M | – | 710 |
|
|
2014
Q4 | $145M | Buy |
2,217,677
+46,750
| +2% | +$2.95M | 0.14% | 143 |
|
|
2014
Q3 | $125M | Buy |
2,170,927
+305,931
| +16% | +$17M | 0.12% | 163 |
|
|
2014
Q2 | $105M | Sell |
1,864,996
-157,679
| -8% | -$8.27M | 0.1% | 205 |
|
|
2014
Q1 | $104M | Buy |
2,022,675
+564,933
| +39% | +$28.6M | 0.1% | 201 |
|
|
2013
Q4 | $77M | Buy |
+1,457,742
| New | +$71.6M | 0.08% | 234 |
|
Other funds holding ABBV
VCM
VPM
Jennison Associates's ABBV Position: Q1 2026 in Review
Jennison Associates reduced its AbbVie (ABBV) stake by 10% in Q1 2026, selling an estimated $27.6M and leaving 1,062,732 shares worth $231M. The position accounts for 0.16% of the portfolio, ranked #64.
Jennison Associates first reported a position in ABBV in Q4 2013 and has held it in 41 quarters since. The position peaked at $1.1B in Q4 2017. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Jennison Associates held 1,062,732 shares of AbbVie worth $231M as of Q1 2026.
- Jennison Associates sold 124,242 AbbVie shares in Q1 2026, an estimated $27.6M.
- AbbVie made up 0.16% of Jennison Associates's portfolio in Q1 2026, its #64 holding.
- Jennison Associates first reported a position in AbbVie in Q4 2013 and has held it in 41 quarters since.
- Jennison Associates's AbbVie position peaked at $1.1B in Q4 2017.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.